01 — At a Glance
The IPO that Arrived Just as Growth Stocks Became Toxic
- 52-Week High / Low₹1,876 / ₹1,226
- Q3 FY26 Revenue₹815 Cr
- Q3 FY26 PAT₹183 Cr
- Q3 FY26 EPS₹10.68
- Annualised EPS (Q3×4)₹42.72
- Book Value₹131
- Price to Book10.5x
- Dividend Yield0.00%
- Debt / Equity0.34x
- IPO Price (Dec 2024)₹133
Fresh IPO Realisation: IKS went public at ₹133 per share (₹2,498 cr IPO size). In 10 weeks, the stock climbed to ₹1,876, rewarding early subscribers with 1,312% gains. Then reality set in. The market recalibrated growth multiples. Today at ₹1,373, the stock still trades 10.3x book value — a hefty premium for a company that was literally unknown three months before listing. Q3 FY26 delivered 24% revenue growth (₹815 cr, ₹19 bn in constant USD), 41% PAT growth to ₹183 cr (₹21.8 bn USD), and adjusted PAT of ₹215 cr after backing out a one-time debt refinancing write-off. The question isn’t whether the business is growing. It is. The question is whether it’s worth 35.4x P/E when the company itself admits it won’t give guidance and considers “unpredictable hiccups” part of the operating model.
02 — Introduction
The Healthcare Startup That Turned 20 Years Old. And Then Got Very Rich Very Suddenly.
Inventurus Knowledge Solutions was founded in 2006. For eighteen years, it quietly built a technology platform that helps US healthcare providers do their most boring job really well: extracting money from patients and insurers. They call it “care enablement,” but honestly, it’s “denial management, prior authorization, medical coding, and revenue cycle optimization told through a tech platform.”
The company operates in the United States primarily, with a small Canadian and Australian footprint. Its main TAM is defined as $260 billion — the total cost of healthcare provider administration that is either performed in-house or is being outsourced to vendors. Of that, $35 billion is already outsourced, and that market grows at 12% CAGR. IKS Management’s heuristic is dead simple: if we grow faster than 12%, we’re gaining share. If we grow slower, we’re not. Guess what? IKS grew 19–24% in the last three quarters. You do the math.
Then came December 2024. BP-owned Castrol India was selling to a PE firm, Stonepeak. In the same week, IKS went public in India. A US healthcare IT company. Listing on NSE. Running a US-focused business. The IPO was 18,795,510 shares at ₹133 each, aggregating ₹2,498 crore. Retail flipped it hard. Institutions chased. The stock split into two: the believers (who held from ₹133 to ₹1,876) and the doubters (who watched from ₹1,876 down to ₹1,226, then stabilizing near ₹1,373). Today, the stock is up ~932% from IPO but down 27% from its 52-week high.
The company has 640+ healthcare clients in the US, employs 12,661 people (down 1.5% YoY, but that’s intentional headcount optimization), and processes millions of patient encounters annually through its proprietary tech stack: Scribble (clinical documentation), Stacks (medical coding), Optimix (patient access and revenue cycle), QCode (coding), and a dozen other acronyms. It’s boring. It works. And right now, its stock is the most volatile thing in the Indian brokerage screens.
The Great Irony: IKS claims AI is a massive tailwind because their revenue model is value-based (tied to quantifiable outcomes, not hours worked). AI makes those outcomes better. Efficiency translates directly to EBITDA. Yet the stock has been caned 27% from its peak as growth stocks face investor rotation. If the market believed its own narrative, the stock should be at ₹2,500. The fact that it isn’t is either the market being rational (this valuation is already stretched) or irrational (temporary phase until rate cuts restore growth-stock appetite). Pick your poison.
03 — Business Model: Why US Doctors Outsource Their “Chore Tasks”
Revenue Cycle = The Business That Pays Healthcare Bills. IKS Automates It. That’s The Whole Story.
Revenue cycle management is the unsexy backbone of every healthcare organization. A patient walks in. Gets treated. Incurs charges. Now someone has to code that visit (medical coding), get approval from the insurer (prior authorization), bill the patient (patient access), and then chase the payment (revenue cycle management). Errors here = lost revenue. Delays here = cash flow problems. Complexity here = hiring armies of FTEs.
IKS does all of this through three key stages: Pre-Visit (patient eligibility, insurance verification, prior authorization), Peri-Visit (clinical documentation via AI, medical coding), and Post-Visit (billing, denial management, accounts receivable). They sell this as a platform. Large healthcare systems in the US are mostly in-house. Small and mid-size providers increasingly outsource. IKS has 85%+ of its revenue from repeat customers (customer retention) and serves 640+ organizations ranging from single-specialty groups to massive health systems like Advent Health and Revere Health.
The proprietary tech stack matters. Scribble is their ambient clinical documentation tool—it listens to the doctor-patient encounter and auto-generates the clinical note via generative AI. No manual transcription. Stacks is autonomous medical coding. Optimix handles patient financial clearance and prior authorization. These aren’t point solutions; they’re workflow orchestration tools that reduce friction across the entire revenue cycle.
Revenue per Qtr₹815 CrQ3 FY26
PAT per Qtr₹183 CrQ3 FY26
Clients Served640+Healthcare Orgs
Repeat Revenue85%+Customer Stickiness
AQuity Acquisition Note (Nov 2023): IKS acquired AQuity for ~$146 million debt. AQuity brings health systems vertical (which Point solutions can’t touch). Integration is “more or less complete,” and management says another couple of quarters to finish customer tail-pruning and cross-sell optimization. This is strategically important because health systems have different buying behavior — they want platforms, not point solutions. IKS is positioning Scribble + Stacks + Optimix as a platform, though they admit they’ll quickly pivot to point-solution pain points for large buyers who still think segmented.
💬 What do you think is riskier: a healthcare automation company with AI tailwinds, or a fresh IPO in a high-rate environment? Drop your take in the comments!
04 — Financials Overview
Q3 FY26: Revenue Growth is Real. The Premium You’re Paying for It Might Not Be.
Result type: Quarterly Results | Q3 FY26 EPS: ₹10.68 | Annualised EPS (Q3×4): ₹42.72 | Full-year FY25 EPS: ₹28.33
| Metric (₹ Mn) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 8,150 | 6,571 | 7,811 | +24.0% | +4.3% |
| Operating Profit | 2,814 | 1,886 | 2,389 | +49.1% | +17.8% |
| OPM % | 34% | 29% | 31% | +500 bps | +300 bps |
| PAT (Reported) | 1,833 | 1,299 | 1,807 | +41.1% | +1.4% |
| PAT (Adjusted)* | 2,155 | — | 1,984 | — | +8.6% |
| EPS (₹) | 10.68 | 7.56 | 10.53 | +41.3% | +1.4% |
* Adjusted PAT excludes INR 127.5 crore one-time non-cash write-off related to AQuity debt refinancing (accelerated amortization of setup costs). This item sat in finance costs. Reported EPS: ₹10.68. Adjusted EPS: ₹12.57 (implied from adjusted PAT of ₹215 cr).
The P/E Recalculation: Annualised Q3 EPS = ₹10.68 × 4 = ₹42.72. CMP ₹1,373 ÷ ₹42.72 = P/E 32.1x (annualised). Industry median P/E for IT services: 22.7x. IKS premium: 41%. That’s not unreasonable for a 24% revenue grower with 41% PAT growth. But it’s also betting that growth sustains. Management explicitly said: “If I said everything is a tailwind and linear growth consistently, I’d be lying. I don’t know when the next hiccup is coming, which is why we don’t give guidance.” Translation: they’re admitting unpredictability. That’s either humble or a massive red flag depending on how much of your portfolio is allocated to this stock.
05 — Valuation Discussion: Fair Value Range
Is This Stock Worth 35.4x P/E, or Did We Just Get Caught in the IPO Momentum Trap?
Join 10,000+ investors who read this every week.
